{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:34:42Z","timestamp":1792985682367,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","award":["RGC TRS T12-705-24-R"],"award-info":[{"award-number":["RGC TRS T12-705-24-R"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","award":["C5017-24G"],"award-info":[{"award-number":["C5017-24G"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-64860-7","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:24:13Z","timestamp":1762863853000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Wild-type KRAS activation drives evasion of interferon-mediated immunity and resistance to immunotherapy in hepatocellular carcinoma"],"prefix":"10.1038","volume":"16","author":[{"given":"Martina Mang Leng","family":"Lei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3878-7150","authenticated-orcid":false,"given":"Carmen Oi Ning","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainbow Wing Hei","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue Qian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7703-0895","authenticated-orcid":false,"given":"Katherine Po Sin","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine Yu Jia","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy Sze Man","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing Ki","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan Hua","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3594-8956","authenticated-orcid":false,"given":"Kai Yu","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5725-0391","authenticated-orcid":false,"given":"Man","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1001-0769","authenticated-orcid":false,"given":"Jing Ping","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia Ming Nickolas","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6347-0005","authenticated-orcid":false,"given":"Guang Sheng","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2895-2789","authenticated-orcid":false,"given":"Patrick Pak Chun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8998-5480","authenticated-orcid":false,"given":"Stephen Lam","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe Wen","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred Sze Lok","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2029-7943","authenticated-orcid":false,"given":"Stephanie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0682-322X","authenticated-orcid":false,"given":"Terence Kin Wah","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"64860_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca. Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"Ca. Cancer J. Clin."},{"key":"64860_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa, G. K. et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 379, 54\u201363 (2018).","journal-title":"N. Engl. J. Med."},{"key":"64860_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0207132","volume":"13","author":"A Shlomai","year":"2018","unstructured":"Shlomai, A., Leshno, M. & Goldstein, D. A. Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib\u2014A cost-effectiveness analysis. PLoS ONE 13, 1\u201311 (2018).","journal-title":"PLoS ONE"},{"key":"64860_CR4","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894\u20131905 (2020).","journal-title":"N. Engl. J. Med."},{"key":"64860_CR5","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00535-020-01668-w","volume":"55","author":"M Kudo","year":"2020","unstructured":"Kudo, M. et al. Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial. J. Gastroenterol. 55, 627\u2013639 (2020).","journal-title":"J. Gastroenterol."},{"key":"64860_CR6","doi-asserted-by":"publisher","unstructured":"Abou-Alfa, G. K. et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J. Clin. Oncol. 40, https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.379 (2022).","DOI":"10.1200\/JCO.2022.40.4_suppl.379"},{"key":"64860_CR7","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry, A. B. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 389, 2492\u20132502 (2017).","journal-title":"Lancet"},{"key":"64860_CR8","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger, S., Bao, R. & Gajewski, T. F. Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity. Nature 523, 231\u2013235 (2015).","journal-title":"Nature"},{"key":"64860_CR9","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","volume":"6","author":"W Peng","year":"2016","unstructured":"Peng, W. et al. Loss of PTEN promotes resistance to T cell\u2013mediated immunotherapy. Cancer Discov. 6, 202\u2013216 (2016).","journal-title":"Cancer Discov."},{"key":"64860_CR10","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","volume":"153","author":"D Sia","year":"2017","unstructured":"Sia, D. et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. Gastroenterology 153, 812\u2013826 (2017).","journal-title":"Gastroenterology"},{"key":"64860_CR11","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1158\/1078-0432.CCR-18-2293","volume":"25","author":"JJ Harding","year":"2019","unstructured":"Harding, J. J. et al. Prospective genotyping of hepatocellular carcinoma: Clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin. Cancer Res. 25, 2116\u20132126 (2019).","journal-title":"Clin. Cancer Res."},{"key":"64860_CR12","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","volume":"9","author":"MR de Galarreta","year":"2019","unstructured":"de Galarreta, M. R. et al. -catenin activation promotes immune escape and resistance to anti\u2013PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 9, 1124\u20131141 (2019).","journal-title":"Cancer Discov."},{"key":"64860_CR13","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1136\/gutjnl-2017-314032","volume":"67","author":"J Zhou","year":"2018","unstructured":"Zhou, J. et al. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immunecheckpoint blockade efficacy. Gut 67, 931\u2013944 (2018).","journal-title":"Gut"},{"key":"64860_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00530-7","volume":"8","author":"DKC Chiu","year":"2017","unstructured":"Chiu, D. K. C. et al. Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2\/CD39L1 in hepatocellular carcinoma. Nat. Commun. 8, 517 (2017).","journal-title":"Nat. Commun."},{"key":"64860_CR15","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1158\/0008-5472.CAN-22-0232","volume":"83","author":"R Dhanasekaran","year":"2023","unstructured":"Dhanasekaran, R. et al. MYC Overexpression drives immune evasion in hepatocellular carcinoma that is reversible through restoration of proinflammatory macrophages. Cancer Res. 83, 626\u2013640 (2023).","journal-title":"Cancer Res."},{"key":"64860_CR16","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","volume":"169","author":"DA Wheeler","year":"2017","unstructured":"Wheeler, D. A. & Roberts, L. R. Comprehensive and integrative genomic characterization of hepatocellular Carcinoma. Cell 169, 1327\u20131341 (2017).","journal-title":"Cell"},{"key":"64860_CR17","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41586-024-07054-3","volume":"627","author":"L Chen","year":"2024","unstructured":"Chen, L. et al. Deep whole-genome analysis of 494 hepatocellular carcinomas. Nature 627, 586\u2013593 (2024).","journal-title":"Nature"},{"key":"64860_CR18","doi-asserted-by":"publisher","unstructured":"Thompson, J. C. et al. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma. J. Immunother. Cancer 8, https:\/\/doi.org\/10.1136\/jitc-2020-000974 (2020).","DOI":"10.1136\/jitc-2020-000974"},{"key":"64860_CR19","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.immuni.2021.01.012","volume":"54","author":"AJ Ozga","year":"2021","unstructured":"Ozga, A. J., Chow, M. T. & Luster, A. D. Chemokines and the immune response to cancer. Immunity 54, 859\u2013874 (2021).","journal-title":"Immunity"},{"key":"64860_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0511-6","volume":"7","author":"Q Gao","year":"2019","unstructured":"Gao, Q. et al. Cancer-cell-secreted CXCL11 promoted CD8 + T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC. J. Immunother. Cancer 7, 1\u201317 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"64860_CR21","first-page":"1","volume":"40","author":"MD L\u00f3pez","year":"2018","unstructured":"L\u00f3pez, M. D. et al. The relationship between chemokines CCL2, CCL3, and CCL4 with the tumor microenvironment and tumor-associated macrophage markers in colorectal cancer. Tumor Biol. 40, 1\u201312 (2018).","journal-title":"Tumor Biol."},{"key":"64860_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41586-022-05400-x","volume":"612","author":"R Xue","year":"2022","unstructured":"Xue, R. et al. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature 612, 141\u2013147 (2022).","journal-title":"Nature"},{"key":"64860_CR23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/ijc.11681","volume":"109","author":"D Atkins","year":"2004","unstructured":"Atkins, D. et al. MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int. J. Cancer 109, 265\u2013273 (2004).","journal-title":"Int. J. Cancer"},{"key":"64860_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.molimm.2013.11.020","volume":"58","author":"JJ El-Jawhari","year":"2013","unstructured":"El-Jawhari, J. J. et al. Blocking oncogenic RAS enhances tumour cell surface MHC class I expression but does not alter susceptibility to cytotoxic lymphocytes. Mol. Immunol. 58, 160\u2013168 (2013).","journal-title":"Mol. Immunol."},{"key":"64860_CR25","first-page":"603","volume":"3","author":"DA Franklin","year":"2020","unstructured":"Franklin, D. A., James, J. L., Axelrod, M. L. & Balko, J. M. MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression. Cancer Drug Resist. 3, 603\u2013612 (2020).","journal-title":"Cancer Drug Resist."},{"key":"64860_CR26","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1136\/gutjnl-2022-328364","volume":"72","author":"Z Xiong","year":"2023","unstructured":"Xiong, Z. et al. Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma. Gut 72, 1758\u20131773 (2023).","journal-title":"Gut"},{"key":"64860_CR27","doi-asserted-by":"publisher","unstructured":"Loboda, A. et al. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. BMC Med. Genomics 3, https:\/\/doi.org\/10.1186\/1755-8794-3-26 (2010).","DOI":"10.1186\/1755-8794-3-26"},{"key":"64860_CR28","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","volume":"28","author":"AX Zhu","year":"2022","unstructured":"Zhu, A. X. et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat. Med. 28, 1599\u20131611 (2022).","journal-title":"Nat. Med."},{"key":"64860_CR29","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrd.2016.139","volume":"15","author":"JM Ostrem","year":"2016","unstructured":"Ostrem, J. M. & Shokat, K. M. Direct small-molecule inhibitors of KRAS: From structural insights to mechanism-based design. Nat. Rev. Drug Discov. 15, 771\u2013785 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"64860_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-022-01629-2","volume":"21","author":"C Zhu","year":"2022","unstructured":"Zhu, C. et al. Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Mol. Cancer 21, 1\u201319 (2022).","journal-title":"Mol. Cancer"},{"key":"64860_CR31","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575, 217\u2013223 (2019).","journal-title":"Nature"},{"key":"64860_CR32","doi-asserted-by":"publisher","first-page":"9678","DOI":"10.1021\/acs.jmedchem.2c00741","volume":"65","author":"JM Ketcham","year":"2022","unstructured":"Ketcham, J. M. et al. Design and discovery of MRTX0902, a potent, selective, brain-penetrant, and orally bioavailable inhibitor of the SOS1:KRAS protein-protein interaction. J. Med. Chem. 65, 9678\u20139690 (2022).","journal-title":"J. Med. Chem."},{"key":"64860_CR33","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1158\/1538-7445.AM2023-3499","volume":"87","author":"S Khare","year":"2023","unstructured":"Khare, S. et al. Abstract 3499: Inhibition of SOS1 by MRTX0902 augments the anti-tumor response of the targeted EGFR inhibitor osimertinib in NSCLC. Cancer Res. 87, 3499 (2023).","journal-title":"Cancer Res."},{"key":"64860_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-018-0049-y","volume":"2","author":"WJ Jeong","year":"2018","unstructured":"Jeong, W. J., Ro, E. J. & Choi, K. Y. Interaction between Wnt\/\u03b2-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of \u03b2-catenin and RAS by targeting the Wnt\/\u03b2-catenin pathway. NPJ Precis. Oncol. 2, 5 (2018).","journal-title":"NPJ Precis. Oncol."},{"key":"64860_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00535-013-0907-x","volume":"49","author":"C Berasain","year":"2014","unstructured":"Berasain, C. & Avila, M. A. The EGFR signalling system in the liver: From hepatoprotection to hepatocarcinogenesis. J. Gastroenterol. 49, 9\u201323 (2014).","journal-title":"J. Gastroenterol."},{"key":"64860_CR36","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1136\/gutjnl-2017-315402","volume":"67","author":"P Dietrich","year":"2018","unstructured":"Dietrich, P. et al. Wild type Kirsten rat sarcoma is a novel microRNA- 622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance. Gut 67, 1328\u20131341 (2018).","journal-title":"Gut"},{"key":"64860_CR37","first-page":"1","volume":"10","author":"HJ Xiong","year":"2023","unstructured":"Xiong, H. J. et al. Elevated FBXL6 activates both wild-type KRAS and mutant KRASG12D and drives HCC tumorigenesis via the ERK\/mTOR\/PRELID2\/ROS axis in mice. Mil. Med. Res. 10, 1\u201321 (2023).","journal-title":"Mil. Med. Res."},{"key":"64860_CR38","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s11427-019-9580-5","volume":"63","author":"W Xu","year":"2020","unstructured":"Xu, W. et al. Ribosome profiling analysis identified a KRAS-interacting microprotein that represses oncogenic signaling in hepatocellular carcinoma cells. Sci. China Life Sci. 63, 529\u2013542 (2020).","journal-title":"Sci. China Life Sci."},{"key":"64860_CR39","doi-asserted-by":"publisher","first-page":"895","DOI":"10.3350\/cmh.2024.0364","volume":"30","author":"YH Jung","year":"2024","unstructured":"Jung, Y. H. et al. KCTD17-mediated Ras stabilization promotes hepato-cellular carcinoma progression. Clin. Mol. Hepatol. 30, 895\u2013913 (2024).","journal-title":"Clin. Mol. Hepatol."},{"key":"64860_CR40","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jhep.2019.08.017","volume":"72","author":"S Rebouissou","year":"2020","unstructured":"Rebouissou, S. & Nault, J. C. Advances in molecular classification and precision oncology in hepatocellular carcinoma. J. Hepatol. 72, 215\u2013229 (2020).","journal-title":"J. Hepatol."},{"key":"64860_CR41","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.cell.2017.11.013","volume":"171","author":"RM Kortlever","year":"2017","unstructured":"Kortlever, R. M. et al. Myc Cooperates with ras by programming inflammation and immune suppression. Cell 171, 1301\u20131315 (2017).","journal-title":"Cell"},{"key":"64860_CR42","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ccell.2019.02.008","volume":"35","author":"W Liao","year":"2019","unstructured":"Liao, W. et al. KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer. Cancer Cell 35, 559\u2013572 (2019).","journal-title":"Cancer Cell"},{"key":"64860_CR43","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","volume":"13","author":"SB Kemp","year":"2023","unstructured":"Kemp, S. B. et al. Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer. Cancer Discov. 13, 298\u2013311 (2023).","journal-title":"Cancer Discov."},{"key":"64860_CR44","doi-asserted-by":"publisher","unstructured":"Mugarza, E. et al. Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers. Sci. Adv. 8, https:\/\/doi.org\/10.1126\/sciadv.abm8780 (2022).","DOI":"10.1126\/sciadv.abm8780"},{"key":"64860_CR45","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","volume":"41","author":"KK Mahadevan","year":"2023","unstructured":"Mahadevan, K. K. et al. KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells. Cancer Cell 41, 1606\u20131620 (2023).","journal-title":"Cancer Cell"},{"key":"64860_CR46","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00262-017-2005-z","volume":"66","author":"N Chen","year":"2017","unstructured":"Chen, N. et al. KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma. Cancer Immunol. Immunother. 66, 1175\u20131187 (2017).","journal-title":"Cancer Immunol. Immunother."},{"key":"64860_CR47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2208900119","volume":"119","author":"LE Stopfer","year":"2022","unstructured":"Stopfer, L. E. et al. MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas. Proc. Natl. Acad. Sci. USA 119, e2208900119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"64860_CR48","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1158\/1541-7786.MCR-19-0545","volume":"17","author":"S Chandrasekaran","year":"2019","unstructured":"Chandrasekaran, S. et al. Phosphoinositide 3-kinase signaling can modulate MHC Class i and II expression. Mol. Cancer Res. 17, 2395\u20132409 (2019).","journal-title":"Mol. Cancer Res."},{"key":"64860_CR49","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/2159-8290.CD-18-0689","volume":"9","author":"S Kitajima","year":"2019","unstructured":"Kitajima, S. et al. Suppression of STING associated with lkb1 loss in KRAS-driven lung cancer. Cancer Discov. 9, 34\u201345 (2019).","journal-title":"Cancer Discov."},{"key":"64860_CR50","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1126\/sciimmunol.abq6509","volume":"7","author":"R Reschke","year":"2022","unstructured":"Reschke, R. & Gajewski, T. F. CXCL9 and CXCL10 bring the heat to tumors. Sci. Immunol. 7, 7\u201310 (2022).","journal-title":"Sci. Immunol."},{"key":"64860_CR51","doi-asserted-by":"publisher","first-page":"46278","DOI":"10.1074\/jbc.M304721200","volume":"278","author":"L Klampfer","year":"2003","unstructured":"Klampfer, L. et al. Oncogenic Ki-Ras inhibits the expression of interferon-responsive genes through inhibition of STAT1 and STAT2 expression. J. Biol. Chem. 278, 46278\u201346287 (2003).","journal-title":"J. Biol. Chem."},{"key":"64860_CR52","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00262-017-2086-8","volume":"67","author":"N Li","year":"2018","unstructured":"Li, N. et al. Cross-talk between TNF-\u03b1 and IFN-\u03b3 signaling in induction of B7-H1 expression in hepatocellular carcinoma cells. Cancer Immunol. Immunother. 67, 271\u2013283 (2018).","journal-title":"Cancer Immunol. Immunother."},{"key":"64860_CR53","doi-asserted-by":"publisher","first-page":"101900","DOI":"10.1016\/j.xcrm.2024.101900","volume":"6","author":"XQ Wu","year":"2025","unstructured":"Wu, X. Q. et al. Intestinal Akkermansia muciniphila complements the efficacy of PD1 therapy in MAFLD-related hepatocellular carcinoma. Cell Rep. Med. 6, 101900 (2025).","journal-title":"Cell Rep. Med."},{"key":"64860_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/srep08053","volume":"5","author":"HL Ju","year":"2015","unstructured":"Ju, H. L. et al. Transgenic mouse model expressing P53R172H, luciferase, EGFP, and KRASG12D in a single open reading frame for live imaging of tumor. Sci. Rep. 5, 8053 (2015).","journal-title":"Sci. Rep."},{"key":"64860_CR55","doi-asserted-by":"publisher","unstructured":"Li, B. & Colin N. Dewey. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinform. 12, https:\/\/doi.org\/10.1186\/1471-2105-12-323 (2011).","DOI":"10.1186\/1471-2105-12-323"},{"key":"64860_CR56","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1093\/bioinformatics\/btz210","volume":"35","author":"B Ru","year":"2019","unstructured":"Ru, B. et al. TISIDB: An integrated repository portal for tumor-immune system interactions. Bioinformatics 35, 4200\u20134202 (2019).","journal-title":"Bioinformatics"},{"key":"64860_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42360-w","volume":"14","author":"CON Leung","year":"2023","unstructured":"Leung, C. O. N. et al. Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma. Nat. Commun. 14, 6699 (2023).","journal-title":"Nat. Commun."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64860-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64860-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64860-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:05:52Z","timestamp":1762869952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64860-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["64860"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-64860-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"26 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9913"}}